NCT05323435View on ClinicalTrials.gov

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

July 5, 2022

Study Completion Date

January 16, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant two-component COVID-19 vaccine (CHO cell)

Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter

BIOLOGICAL

COVID-19 Vaccine (Vero Cell), Inactivated

Milky-white suspension.Stratified precipitate may form which can be dispersed by shaking

Trial Locations (1)

7272

AI Kuwait Hospital, Dubai

All Listed Sponsors
lead

Jiangsu Rec-Biotechnology Co., Ltd.

INDUSTRY